Zeria Pharmaceutical Co Ltd
TSE:4559
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Zeria Pharmaceutical Co Ltd
TSE:4559
|
JP |
|
C
|
Carlos Casado SA
BCBA:CADO
|
AR |
|
Century Communities Inc
NYSE:CCS
|
US |
|
Lantern Pharma Inc.
NASDAQ:LTRN
|
US |
|
Pidilite Industries Ltd
NSE:PIDILITIND
|
IN |
|
S
|
Selangor Dredging Bhd
KLSE:SDRED
|
MY |
|
Microbot Medical Inc
NASDAQ:MBOT
|
US |
|
S
|
Saltlux Inc
KOSDAQ:304100
|
KR |
|
Central Puerto SA
NYSE:CEPU
|
AR |
|
ConnectOne Bancorp Inc
NASDAQ:CNOB
|
US |
|
United Bancshares Inc
OTC:UBOH
|
US |
|
I
|
Inno-Gene SA
WSE:IGN
|
PL |
|
S
|
Sigong Tech Co Ltd
KOSDAQ:020710
|
KR |
|
Z
|
Zapata Computing Holdings Inc
NASDAQ:ZPTA
|
US |
|
C
|
Chesswood Group Ltd
TSX:CHW
|
CA |
Wall Street
Price Targets
Price Targets Summary
Zeria Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for
Zeria Pharmaceutical Co Ltd
is 2 550 JPY
with a low forecast of 2 525 JPY and a high forecast of 2 625 JPY.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is Zeria Pharmaceutical Co Ltd's stock price target?
Price Target
2 550
JPY
According to Wall Street analysts, the average 1-year price target for
Zeria Pharmaceutical Co Ltd
is 2 550 JPY
with a low forecast of 2 525 JPY and a high forecast of 2 625 JPY.
What is Zeria Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
4%
For the last 13 years the
compound annual growth rate for
Zeria Pharmaceutical Co Ltd's revenue is
4%.
The projected
CAGR
for the next 3 years is
4%.
What is Zeria Pharmaceutical Co Ltd's Net Income forecast?
Projected CAGR
8%
For the last 13 years the
compound annual growth rate for
Zeria Pharmaceutical Co Ltd's net income is
10%.
The projected
CAGR
for the next 3 years is
8%.
